Evaluation of the Patient Acceptable Symptom State in a pooled analysis of two multicentre, randomised, double-blind, placebo-controlled studies evaluating lumiracoxib and celecoxib in patients with osteoarthritis

Benzer Materyaller

• Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a 13 week, randomised, double blind study versus placebo and celecoxib
  Yazar:: Tannenbaum, H, ve diğerleri
  Baskı/Yayın Bilgisi: (2004)
• A 6-week, multicentre, randomised, double-blind, double-dummy, active-controlled, clinical safety study of lumiracoxib and rofecoxib in osteoarthritis patients
  Yazar:: Stricker, Kirstin, ve diğerleri
  Baskı/Yayın Bilgisi: (2008)
• Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial
  Yazar:: Zhuang, Qianyu, ve diğerleri
  Baskı/Yayın Bilgisi: (2020)
• First-dose analgesic effect of the cyclo-oxygenase-2 selective inhibitor lumiracoxib in osteoarthritis of the knee: a randomized, double-blind, placebo-controlled comparison with celecoxib [NCT00267215]
  Yazar:: Wittenberg, Ralf H, ve diğerleri
  Baskı/Yayın Bilgisi: (2006)
• Correction: Postoperative intravenous parecoxib sodium followed by oral celecoxib post total knee arthroplasty in osteoarthritis patients (PIPFORCE): a multicentre, double-blind, randomised, placebo-controlled trial
  Baskı/Yayın Bilgisi: (2020)